Special considerations for biologic medications in pediatric ulcerative colitis

References

• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol.2015 Sep 1;12:720.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: A systematic review of international trends. Inflamm Bowel Dis. 2011;17(1):423–439.
   PubMed Web of Science ®Google Scholar
• Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in childhood. Gut [Internet]. 2011;60(1):49–54. Available from: https://gut.bmj.com/content/60/1/49
   PubMed Web of Science ®Google Scholar
• Geerling BJ, Dagnelie PC, Badart-Smook A, et al. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol. 2000;95(4):1008–1013.
   PubMed Web of Science ®Google Scholar
• Roberts CL, Rushworth SL, Richman E, et al. Hypothesis: increased consumption of emulsifiers as an explanation for the rising incidence of Crohn’s disease. J Crohn’s Colitis. 2013;7(4):338–341.
   Google Scholar
• Kappelman MD, Moore KR, Allen JK, et al. Recent trends in the prevalence of Crohn’s disease and ulcerative colitis in a commercially insured US population. Dig Dis Sci. 2013;58(2):519–525.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54.e42. [Internet].
   PubMed Web of Science ®Google Scholar
• Hyams JS, Davis TS, Gotman N, et al. Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study. Lancet. 2019;393(10182):1708–1720. [Internet].
   PubMed Web of Science ®Google Scholar
• Aloi M, D’Arcangelo G, Pofi F, et al. Presenting features and disease course of pediatric ulcerative colitis. J Crohn’s Colitis. 2013;7(11):e509–15. [Internet].
   Google Scholar
• Jakobsen C, Bartek J, Wewer V, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease-a population-based study. Aliment Pharmacol Ther. 2011;34(10):1217–1224.
   PubMed Web of Science ®Google Scholar
• Langholz E, Munkholm P, Krasilnikoff PA, et al. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol. 1997;32(2):139–147.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, To T, Griffiths AM, et al. Outcomes of pediatric inflammatory bowel disease: socioeconomic status disparity in a universal-access healthcare system. J Pediatr. 2011;1586:960–967.e4. [Internet].
   PubMed Web of Science ®Google Scholar
• Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10(4):391–399.e1. [Internet].
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Padgett L, et al. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study. Inflamm Bowel Dis. 2013;19(13):2753–2762.
   PubMed Web of Science ®Google Scholar
• Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138(7):2282–2291. [Internet].
   PubMed Web of Science ®Google Scholar
• Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4(9):1118–1123.
   PubMed Web of Science ®Google Scholar
• Schechter A, Griffiths C, Gana JC, et al. Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut. 2015;64(4):580–588.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Wong-Spracklen V, Torrente F, et al. Early treatment response predicts outcome in paediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2018;67(2):217–220.
   PubMed Web of Science ®Google Scholar
• Falaiye TO, Mitchell KR, Lu Z, et al. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr. 2014;58(2):213–219.
   PubMed Web of Science ®Google Scholar
• Nattiv R, Wojcicki JM, Garnett EA, et al. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol. 2012;18(11):1229–1234.
   PubMed Web of Science ®Google Scholar
• Whaley KG, Rosen MJ. Contemporary medical management of acute severe ulcerative colitis. Inflamm Bowel Dis. 2019;25(1):56–66.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296–1307.e5. [Internet].
   PubMed Web of Science ®Google Scholar
• Vande CN, Ferrante M, Van AG, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease; Gastroenterology. 2015. p. 1320–1329.
   Google Scholar
• Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut. 2010;59(1):49–54.
   PubMed Web of Science ®Google Scholar
• Choi SY, Kang B, Lee JH, et al. Clinical use of measuring trough levels and antibodies against infliximab in patients with pediatric inflammatory bowel disease. Gut Liver. 2017;11(1):55.
   PubMed Web of Science ®Google Scholar
• Hofmekler T, Bertha M, McCracken C, et al. Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017;64(4):580–585.
   PubMed Web of Science ®Google Scholar
• Naviglio S, Lacorte D, Lucafò M, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. J Pediatr Gastroenterol Nutr. 2019;68(1):37–44.
   PubMed Web of Science ®Google Scholar
• Ungar B, Mazor Y, Weisshof R, et al. Induction infliximab levels among patients with acute severe ulcerative colitis compared with patients with moderately severe ulcerative colitis. Aliment Pharmacol Ther. 2016;43(12):1293–1299.
   PubMed Web of Science ®Google Scholar
• Hindryckx P, Novak G, Vande Casteele N, et al. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017;45(5):617–630.
   PubMed Web of Science ®Google Scholar
• Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: A population pharmacokinetic study. Inflamm Bowel Dis. 2014;20(12):2247–2259.
   PubMed Web of Science ®Google Scholar
• Church PC, Ho S, Sharma A, et al. Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis. J Crohn’s Colitis. 2019;13:982–989.
   Google Scholar
• Turner D, Griffiths AM, Veerman G, et al. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11(11):1460–1465. [Internet].
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn’s disease? A decision analysis. Inflamm Bowel Dis. 2013;19(1):37–44.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56(4):453–455.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;149:1245–1255.e8. [Internet].
   PubMed Web of Science ®Google Scholar
• Chang KH, Burke JP, Coffey JC. Infliximab versus cyclosporine as rescue therapy in acute severe steroid-refractory ulcerative colitis: A systematic review and meta-analysis. Int J Colorectal Dis. 2013;28(3):287–293.
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Barthel DN, Schmidt KJ, et al. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther. 2010;31(9):1036–1041.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Dubinsky MC, Baldassano RN, et al. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901–1914.e3.
   PubMed Web of Science ®Google Scholar
• Steiner SJ, Liu C, King E, et al. Su2022 - evaluation of adalimumab effectiveness in pediatric patients with ulcerative colitis in clinical practice. Gastroenterology. 2018;154:S-668–S-669. Elsevier Inc.
   Web of Science ®Google Scholar
• Volonaki E, Mutalib M, Kiparissi F, et al. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol Hepatol. 2015;27(12):1425–1428.
   PubMed Web of Science ®Google Scholar
• Aloi M, Bramuzzo M, Arrigo S, et al. Efficacy and safety of adalimumab in pediatric ulcerative colitis: a real-life experience from the SIGENP-IBD registry. J Pediatr Gastroenterol Nutr. 2018;66(6):920–925.
   PubMed Web of Science ®Google Scholar
• Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017;45(10):1291–1302.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109.e1. [Internet].
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95. Internet. .
   PubMed Web of Science ®Google Scholar
• Hyams JS, Chan D, Adedokun OJ, et al. Subcutaneous golimumab in pediatric ulcerative colitis: pharmacokinetics and clinical benefit. Inflamm Bowel Dis. 2017;23(12):2227–2237.
   PubMed Web of Science ®Google Scholar
• Xu Y, Adedokun OJ, Chan D, et al. Population pharmacokinetics and exposure-response modeling analyses of golimumab in children with moderately to severely active ulcerative colitis. J Clin Pharmacol. 2019;59(4):590–604.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. [Internet].
   PubMed Web of Science ®Google Scholar
• Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(9):2121–2126.
   PubMed Web of Science ®Google Scholar
• Conrad MA, Stein RE, Maxwell EC, et al. Vedolizumab therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–2431.
   PubMed Web of Science ®Google Scholar
• Schneider AM, Weghuber D, Hetzer B, et al. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. BMC Gastroenterol. 2018;18(1):1–7.
   PubMedGoogle Scholar
• Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut. 2014;63(8):1258–1264.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007;56(9):1226–1231.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U, Engel T, et al. Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2017;45(2):276–282.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.
   PubMed Web of Science ®Google Scholar
• Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55(3):340–361.
   PubMed Web of Science ®Google Scholar
• Sarikaya Hadi İ, Bektaṣ Hadi A, İbiṣ Hadi E, et al. Tc-99m dextran and tc-99m HIG findings in patients with ulcerative colitis. Clin Nucl Med. 1999;24(4):243–247.
   PubMed Web of Science ®Google Scholar
• Brandse JF, van Den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–355.
   PubMed Web of Science ®Google Scholar
• Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr Internet. 2007;44(3):312–317. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=17325550%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed8&NEWS=N&AN=2007214096
   PubMed Web of Science ®Google Scholar
• Mor IJ, Vogel JD, Da Luz Moreira A, et al. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2008;51(8):1202–1207.
   PubMed Web of Science ®Google Scholar
• Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50(11):1747–1753.
   PubMed Web of Science ®Google Scholar
• Kennedy R, Potter DD, Moir C, et al. Pediatric chronic ulcerative colitis : does infliximab increase post – ileal pouch anal anastomosis complications? J Pediatr Surg. 2012;471:199–203. [Internet].
   PubMed Web of Science ®Google Scholar